Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1α-hydroxyvitamin D5

Carcinogenesis

Volumn 28, Issue 5, 2007, Pages 1000-1007

  Peng, Xinjian ^b   Jhaveri, Pavan ^a   Hussain Hakimjee, Erum A ^a   Mehta, Rajendra G ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b IIT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA HYDROXYVITAMIN D5; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; 1 HYDROXYVITAMIN D5; 1-HYDROXYVITAMIN D5; CALCITRIOL RECEPTOR; HYDROXYCOLECALCIFEROL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESPONSE; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; METABOLISM;

BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; HYDROXYCHOLECALCIFEROLS; RECEPTORS, CALCITRIOL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 34447108091     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl230     Document Type: Article

References (30)

1. Couse, J.F. et al. (1999) Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev., 20, 358-417.
2. Jordan, V.C. (1995) Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer" - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res. Treat, 36, 267-285.
3. MacGregor, J.I. et al. (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev., 50, 151-196.
4. Peng, X. et al. (2004) A novel RARβ isoform directed by a distinct promoter P3 and mediated by retinoic acid in breast cancer cells. Cancer Res., 64, 8911-8918.
5. Hussain-Hakirnjee, E.A. et al. (2006) Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone, sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5. Carcinogenesis, 27, 551-559.
6. Stoica, A. et al. (1999) Regulation of estrogen receptor-alpha gene expression by 1, 25-dihydroxyvitamin D in MCF-7 cells. J. Cell. Biochem., 72, 640-651.
7. Swami, S. et al. (2000) 1alpha, 25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin. Cancer Res., 6, 3371-3379.
8. Simboli-Campbell, M. et al. (1997) Comparative effects of 1, 25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat, 42, 31-41.
9. Jensen, S.S, et al. (2002) Sensitivity to growth suppression by 1alpha, 25-dihydroxyvitamin D(3) among MCF-7 clones correlates with vitamin D receptor protein induction J. Steroid Biochem. Mol. Biol. 81, 123-133.
10. Narvaez, C.J. et al. (1996) Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology, 137, 400-409.
11. Hansen, C.M. et al. (2001) MCF-7/VD(R): A new vitamin D resistant cell line. J. Cell. Biochem., 82, 422-436.
12. Swami, S. et al. (2003) Vitamin D growth inhibition of breast cancer cells: Gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat, 80, 49-62.
13. 5) in breast cancer prevention and therapy. Recent Results Cancer Res., 64, 393-411.
14. Colston, K.W. et al. (2001) Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr. Relat. Cancer, 9, 45-59.
15. Jiang, S.Y. et al. (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst., 84, 580-591.
16. Mehta, R.G. et al. (1997) Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxy-vitamin D5. J. Natl Cancer Inst., 89, 212-218.
17. Peng, X. et al. (2005) Retinoids suppress premalignant MCF10AT but not malignant MCF10CA1a breast epithelial cells in vivo. Role of retinoic acid receptor β2 expression. Cancer Lett., 222, 153-163.
18. van den Bemd, G.C. et al. (1996) Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060. Proc. Natl Acad. Sci. USA, 93, 10685-10690.
19. Tsai, M.J. et al. (1994) Molecular mechanisms of action of steroid/ thyroid receptor supper family members. Annu. Rev. Biochem., 63, 451-486.
20. Flanagan, L. et al. (2003) Efficacy of vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J. Steroid Biochem. Mol. Biol., 84, 181-192.
21. Peng, X. et al. (2006) Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res., 66, 7361-7369.
22. Maenpaa, P.H. et al. (2001) Vitamin D(3) analogs (MC 1288, KH 1060, EB 1089, GS 1558, and CB 1093): Studies on their mechanism of action. Steroids, 66, 223-225.
23. Tonetti, D.A. et al. (2003) Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J. Steroid Biochem. Mol. Biol., 87, 47-55.
24. Banwell, C.M. et al. (2004) Targeting 1alpha, 25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. J. Steroid Biochem. Mol. Biol., 89-90, 245-249.
25. Polly, P. et al. (2000) VDR-Alien: A novel, DNA-selective vitamin D(3) receptor-compressor partnership. FASEB J, 14, 1455-1463.
26. Leo, C. et al. (2000) The SRC family of nuclear receptor coactivators. Gene, 245, 1-11.
27. Carlberg, C. (2004) Ligand-mediated conformational changes of the VDR are required for gene transactivation. J. Steroid Biochem. Mol. Biol. 89-90, 227-232.
28. Banwell, C.M. et al. (2006) Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin. Cancer Res., 12, 2004-2013.
29. Saramaki, A. et al. (2006)Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res., 34, 543-554.
30. Bettoun, D.J. et al. (2003) Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation. Mol. Endocrinol, 17, 2320-2328.